TEVA, US8816242098

JPMorgan raised target for Teva stock to USD 50.00

Published on 10/13/2026 at 09:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan lifted its target from USD 40.00 to USD 50.00 on October 11, 2026. November 3, 2026 tests Teva stock.

Key points in brief

JPMorgan raised its Teva target from USD 40.00 to USD 50.00 on October 11, 2026.
Oppenheimer set a USD 52.00 target on October 9, 2026, while TD Cowen set USD 55.00 on October 1, 2026.
Teva reported USD 4.14 billion in second-quarter 2026 revenue and a USD 576.0 million net loss.
Third-quarter 2026 results and the investor call are scheduled for November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva (ISIN US8816242098) received a higher JPMorgan target of USD 50.00, up from USD 40.00, in a note dated October 11, 2026. Markets Insider reported that JPMorgan kept its Overweight rating and linked the increase to Weltruza, Teva's newly approved long-acting olanzapine treatment.

Three targets in eleven days

On October 1, 2026, TD Cowen began coverage with a Buy rating and a USD 55.00 target, according to Markets Insider.

On October 9, 2026, Oppenheimer raised its target from USD 50.00 to USD 52.00 and maintained an Outperform rating, as Investing.com reported. The three target levels put product execution ahead of short-term share-price commentary.

What does Weltruza change?

Investing.com reported on October 9, 2026 that Teva set Weltruza's monthly wholesale acquisition cost at USD 3,950, which was 47.00 percent above Oppenheimer's initial assumption. The report said the launch is expected to begin in the first half of 2027, with meaningful revenue generation expected in the second half of 2027.

The latest reported quarter also sets a demanding baseline. Teva generated USD 4.14 billion of revenue in the second quarter of 2026, down from USD 4.18 billion a year earlier, while net income attributable to common shareholders was a USD 576.0 million loss, according to Yahoo Finance. That combination makes the 2027 launch timetable and the commercial uptake of Weltruza central to the next valuation debate.

November brings the next test

Teva is scheduled to release third-quarter 2026 results on November 3, 2026, at 7:00 a.m. ET and hold its conference call at 8:00 a.m. ET. The date and times were published by Teva on September 23, 2026.

For investors, the immediate question is whether the next results can support the higher target range while Teva prepares a measured Weltruza launch. The combination of a USD 50.00 JPMorgan target, a USD 52.00 Oppenheimer target and a USD 55.00 TD Cowen target gives the upcoming report a clear numerical benchmark.

The further course of trading is shown by the continuously updated real-time quote of Teva stock.